Progress Treating Disease


Every day, thousands of biopharmaceutical researchers and patients go boldly to fight the odds to unearth cutting-edge medicines and cures.

Medicines in Development

Patients with a wide range of life-threatening and debilitating illnesses today live in the hope tomorrow will bring a new medicine that will improve or even save their life. America’s Biopharmaceutical Companies are researching and developing new medicines to meet unmet need and continuing research and development even after U.S. Food and Drug Administration (FDA) approval, all with the goal of improving patients’ health, quality of life, and saving lives.

Since 2000, nearly 900 new medicines have been approved by the FDA, helping patients live longer, healthier lives. Among the remarkable new treatments reaching patients are the first gene therapies for devastating rare genetic disorders impacting infants and children, curative treatments for hepatitis C, a range of CAR-T cell therapies driving unprecedented remission rates for cancer patients as well as immunotherapies and targeted therapies widely regarded as driving accelerated drops in cancer mortality for U.S. patients in recent years.

Explore the medicines in development

Scientific innovation

Biopharmaceutical research and development is key to improving patients’ health and saving lives. America’s Biopharmaceutical Companies are tireless in the pursuit of revolutionary treatments and vaccines. Thanks to the innovative medicines they’ve developed, patients all over the world are living longer, healthier and more productive lives. Together, we stand committed to treat and defend against disease in all its forms.

Learn more

Progress Treating Disease

Research does not end once a medicine is approved by the FDA; it is built upon to improve outcomes for patients, simplify treatment regimens and monitor safety. America's Biopharmaceutical Companies are committed to a dynamic research ecosystem that delivers safe and efficacious treatments to patients. 

Explore how far we’ve come

Americas Biopharmaceutical Companies

Every day, thousands of biopharmaceutical researchers and patients go boldly to fight the odds to unearth cutting-edge medicines and cures.

-

Read More

Emerging Value in Oncology

Research and development of cancer medicines after their initial FDA approval can help expand treatment populations, find new ways of treating a cancer or help patients earlier in their cancer battle. Unfortunately, provisions in the Inflation Reduction Act put this progress in jeopardy by selecting medicines for price setting before many of these critical advancements can be fully realized.

-

report
Scientist writing on glass wall

Open Letter from Biopharmaceutical R&D Leaders to the Biden Administration: Your Policies Are Undermining the Cancer Moonshot

America’s biopharmaceutical companies share President Biden’s commitment to eradicating cancer. With more than 1,300 medicines in the research pipeline, the science has never been more promising. But as industry research and development leaders warn in a letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it can get off the ground.

-

Read More
Research In Your Backyard

Research in your Backyard

Across America, biopharmaceutical researchers are conducting clinical trials to help patients connect with potential treatments and new medicines and cures. Learn about clinical trials in your state!

-

Learn From
Teaser image for PhRMA report titled Biopharmaceutical Industry Efforts to Fight COVID-19: Lessons Learned and Preparing for Future Pandemics

Biopharmaceutical Industry Efforts to Fight COVID-19: Lessons Learned and Preparing for Future Pandemics

America’s biopharmaceutical companies came together to achieve one shared goal of fighting COVID-19. The decades-long investments we have made in new technology, research and treatments prepared us to act swiftly.

-

read more
Chemist in laboratory examining a test tube of red liquid

A Decade of Innovation in Rare Diseases

Over the past decade, a new era of innovation has pushed the frontiers of science, leading to remarkable progress for patients with a wide range of rare diseases. Collectively, these diseases impact 30 million Americans and 400 million people worldwide. Despite the challenges, throughout the last decade, America's biopharmaceutical researcher companies have made significant progress in the development of groundbreaking therapies.

-

Fact sheet
Innovation in the Biopharmaceutical Pipeline

Innovation in the Biopharmaceutical Pipeline

The biopharmaceutical pipeline contains thousands of innovative new treatments that have the potential to address unmet medical needs, save lives and improve patients’ health.

-

REport

This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.